DELRAY BEACH, Fla., Aug. 5, 2005 (PRIMEZONE) -- Hard to Treat Diseases, Incorporated (HTTD) (Pink Sheets:HTDS) announces today that the Court has denied the Company's Motion to Alter or Amend Memorandum Opinion and Judgment, or, in the alternative, for rehearing.
"It's obvious that common sense, case law and undisputed facts are not sufficient to protect shareholders and to correct the injustice by parties allowed to ignore their fiduciary duties," states HTTD's CEO Colm J. King. "HTTD will continue to defend its shareholders from fraudulent acts."
Complete copies of Court documents can be viewed on the Company's website at: www.htdsotc.com. Click on Corporate, then click on Legal.
King, states, "In light of the Court's decision, the Company will decide the most prudent course of action. The company's business strategy and plans will be released as soon as they are finalized. HTTD fully intends to become a respected biotech with the intense focus of negotiating a deal with a major biotech/drug company and attaining the goals of benefiting patients and HTTD's shareholders, the real owners of the Company."
Cautionary Note Regarding Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard to Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.